HRP20170094T1 - Imunogeni pripravak - Google Patents
Imunogeni pripravak Download PDFInfo
- Publication number
- HRP20170094T1 HRP20170094T1 HRP20170094TT HRP20170094T HRP20170094T1 HR P20170094 T1 HRP20170094 T1 HR P20170094T1 HR P20170094T T HRP20170094T T HR P20170094TT HR P20170094 T HRP20170094 T HR P20170094T HR P20170094 T1 HRP20170094 T1 HR P20170094T1
- Authority
- HR
- Croatia
- Prior art keywords
- toxin
- amino acids
- proximal end
- polypeptide according
- polypeptide
- Prior art date
Links
- 230000002163 immunogen Effects 0.000 title claims 9
- 229920001184 polypeptide Polymers 0.000 claims 43
- 102000004196 processed proteins & peptides Human genes 0.000 claims 43
- 108090000765 processed proteins & peptides Proteins 0.000 claims 43
- 150000001413 amino acids Chemical class 0.000 claims 37
- 101710182223 Toxin B Proteins 0.000 claims 19
- 239000012634 fragment Substances 0.000 claims 18
- 101710084578 Short neurotoxin 1 Proteins 0.000 claims 16
- 101710182532 Toxin a Proteins 0.000 claims 16
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 241000193163 Clostridioides difficile Species 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 229960005486 vaccine Drugs 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 claims 1
- 241000606768 Haemophilus influenzae Species 0.000 claims 1
- 241000588650 Neisseria meningitidis Species 0.000 claims 1
- 201000005702 Pertussis Diseases 0.000 claims 1
- 241000191963 Staphylococcus epidermidis Species 0.000 claims 1
- 206010043376 Tetanus Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 206010013023 diphtheria Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000001681 protective effect Effects 0.000 claims 1
- 230000003252 repetitive effect Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (40)
1. Polipeptid koji sadrži prvi fragment i drugi fragment, naznačen time što
(i) prvi fragment je fragment ponavljajuće domene toksina A;
(ii) drugi fragment je fragment ponavljajuće domene toksina B;
(iii) prvi fragment ima prvi proksimalni kraj;
(iv) drugi fragment ima drugi proksimalni kraj; i
gdje prvi fragment i drugi fragment razdvaja manje od ili točno 5 aminokiselina u primarnoj strukturi, gdje polipeptid izaziva pojavu protutijela koja neutraliziraju i toksin A i toksin B, gdje je prvi proksimalni kraj unutar kratke ponavljajuće jedinice i drugi proksimalni kraj je unutar kratke ponavljajuće jedinice, gdje prvi proksimalni kraj i drugi proksimalni kraj ne prekidaju dijelove kratka ponavljajuća jedinica-duga ponavljajuća jedinica-kratka ponavljajuća jedinica.
2. Polipeptid u skladu s patentnim zahtjevom 1, naznačen time što polipeptid izaziva zaštitni imunosni odgovor kod sisavačkog domaćina protiv sojeva bakterije C. difficile.
3. Polipeptid u skladu s bilo kojim od patentnih zahtjeva 1-2, naznačen time što prvi fragment i/ili drugi fragment sadrži manje od 25%, 20%, 18% ili 15% strukture α-uzvojnice.
4. Polipeptid u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što prvi fragment i/ili drugi fragment sadrži više od 25%, 30%, 35%, 38% ili 40% strukture β-ploče.
5. Polipeptid u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što prvi proksimalni kraj nije među aminokiselinama 1878-1940, 2012-2074, 2146-2208, 2258-2322, 2394-2456, 2507-2569 ili 2598-2660 toksina A.
6. Polipeptid u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što drugi proksimalni kraj nije među aminokiselinama 1881-1942, 2012-2074, 2144-2208 ili 2278-2339 toksina B.
7. Polipeptid u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što prvi fragment sadrži najmanje 100, 250, 400 ili 450 aminokiselina.
8. Polipeptid u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što drugi fragment sadrži najmanje 100, 200, 300 ili 400 aminokiselina.
9. Polipeptid u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je prvi proksimalni kraj unutar ponavljajućeg dijela VIII (aminokiseline 2645-2710) toksina A.
10. Polipeptid u skladu s bilo kojim od patentnih zahtjeva 1-9, naznačen time što je prvi proksimalni kraj među aminokiselinama 2700-2710 ili 2680-2690 toksina A.
11. Polipeptid u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je drugi proksimalni kraj unutar ponavljajućeg dijela I (aminokiseline 1834-1926) toksina B.
12. Polipeptid u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je drugi proksimalni kraj među aminokiselinama 1860-1878 ili 1854-1876 toksina B.
13. Polipeptid u skladu s bilo kojim od patentnih zahtjeva 1-10, naznačen time što je drugi proksimalni kraj unutar ponavljajućeg dijela II (aminokiseline 1927-2057) toksina B.
14. Polipeptid u skladu s bilo kojim od patentnih zahtjeva 1-10 ili 13, naznačen time što je drugi proksimalni kraj među aminokiselinama 1960-1970, 1988-1998 ili 1867-1877 toksina B.
15. Polipeptid u skladu s bilo kojim od patentnih zahtjeva 9, 10, 11 ili 12, naznačen time što je prvi proksimalni kraj unutar ponavljajućeg dijela VIII (aminokiseline 2645-2710) toksina A, te što je drugi proksimalni kraj unutar ponavljajućeg dijela I (aminokiseline 1834-1926) toksina B.
16. Polipeptid u skladu s bilo kojim od patentnih zahtjeva 9, 10, 13 ili 14, naznačen time što je prvi proksimalni kraj unutar ponavljajućeg dijela VIII (aminokiseline 2645-2710) toksina A, te što je drugi proksimalni kraj unutar ponavljajućeg dijela II (aminokiseline 1927-2057) toksina B.
17. Polipeptid u skladu s bilo kojim od patentnih zahtjeva 9, 10, 13 ili 14, naznačen time što je prvi proksimalni kraj unutar kratke ponavljajuće jedinice 3 ponavljajućeg dijela VIII toksina A (aminokiseline 2687-2710), a drugi proksimalni kraj je unutar kratke ponavljajuće jedinice 4 ponavljajućeg dijela II toksina B (aminokiseline 1988-2007).
18. Polipeptid u skladu s bilo kojim od patentnih zahtjeva 9, 10, 13 ili 14, naznačen time što je prvi proksimalni kraj unutar kratke ponavljajuće jedinice 2 ponavljajućeg dijela VIII (aminokiseline 2665-2686) toksina A, a drugi proksimalni kraj je unutar kratke ponavljajuće jedinice 3 ponavljajućeg dijela II toksina B (aminokiseline 1968-1987).
19. Polipeptid u skladu s bilo kojim od patentnih zahtjeva 9, 10, 11 ili 12, naznačen time što je prvi proksimalni kraj unutar kratke ponavljajuće jedinice 2 ponavljajućeg dijela VIII toksina A (aminokiseline 2665-2686), a drugi proksimalni kraj je unutar kratke ponavljajuće jedinice 3 ponavljajućeg dijela I toksina B (1877-1896).
20. Polipeptid u skladu s bilo kojim od patentnih zahtjeva 1-8, 9, 10, 11, 12 i 15, naznačen time što je prvi proksimalni kraj unutar kratke ponavljajuće jedinice 3 ponavljajućeg dijela VIII toksina A (aminokiseline 2645-2686), a drugi proksimalni kraj je unutar kratke ponavljajuće jedinice 1 ponavljajućeg dijela I toksina B (aminokiseline 1834-1854).
21. Polipeptid u skladu s bilo kojim od patentnih zahtjeva 9, 10, 13 ili 14, naznačen time što je prvi proksimalni kraj unutar kratke ponavljajuće jedinice 3 ponavljajućeg dijela VIII toksina A (aminokiseline 2687-2710), a drugi proksimalni kraj je unutar kratke ponavljajuće jedinice 4 ponavljajućeg dijela II toksina B (aminokiseline 1988-2007).
22. Polipeptid u skladu s patentnim zahtjevom 16, naznačen time što je prvi proksimalni kraj među aminokiselinama 2700-2710 toksina A, a drugi proksimalni kraj je među aminokiselinama 1960-1970 toksina B.
23. Polipeptid of patentnih zahtjeva 16, naznačen time što je prvi proksimalni kraj među aminokiselinama 2680-2690 toksina A, a drugi proksimalni kraj je među aminokiselinama 1960-1970 toksina B.
24. Polipeptid of patentnih zahtjeva 16, naznačen time što je prvi proksimalni kraj među aminokiselinama 2700-2710 u toksinu A, a drugi proksimalni kraj je među aminokiselinama 1988-1998 toksina B.
25. Polipeptid u skladu s patentnim zahtjevom 16, naznačen time što je prvi proksimalni kraj među aminokiselinama 2680-2690, a drugi proksimalni kraj je među aminokiselinama 1860-1878.
26. Polipeptid u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je polipeptid dio većeg fuzijskog proteina.
27. Polipeptid u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što polipeptid sadrži imunogeni fragment od SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7 SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25 ili SEQ ID NO:27.
28. Polipeptid u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što polipeptid sadrži imunogeni fragment od najmanje 500, 600, 700, 750, 800, 850 ili 900 aminokiselina sa SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7 SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25 ili SEQ ID NO:27.
29. Polipeptid u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što polipeptid sadrži više od 450, 475, 500, 525, 575, 600, 625, 650, 675, 700, 725, 750, 775, 800, 825 ili 850 aminokiselina iz toksina A.
30. Polipeptid u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što polipeptid sadrži manje od 850, 825, 800, 775, 750, 725, 700, 675, 650, 625, ili 600 aminokiselina iz toksina A.
31. Polipeptid u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što polipeptid sadrži više od 350, 375, 400, 425, 450, 475, 500 ili 525 aminokiselina iz toksina B.
32. Polipeptid u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što polipeptid sadrži manje od 525, 500, 475, ili 450 aminokiselina iz toksina B.
33. Polinukleotid, naznačen time što kodira polipeptid u skladu s bilo kojim od patentnih zahtjeva 1-32.
34. Vektor, naznačen time što sadrži polinukleotid u skladu s patentnim zahtjevom 33, naznačen time što je povezan s inducibilnim promotorom.
35. Imunogeni pripravak, naznačen time što sadrži polipeptid u skladu s bilo kojim od patentnih zahtjeva 1-32 i farmaceutski prihvatljivu pomoćnu tvar.
36. Imunogeni pripravak u skladu s patentnim zahtjevom 35, naznačen time što dodatno sadrži adjuvans.
37. Imunogeni pripravak u skladu s bilo kojim od patentnih zahtjeva 35-36, naznačen time što dodatno sadrži dodatne antigene.
38. Imunogeni pripravak u skladu s patentnim zahtjevom 37, naznačen time što su dodatni antigeni antigeni dobiveni iz bakterije koju se bira iz skupine koju čine S. pneumoniae, H. influenzae, N. meningitidis, E. coli, M. cattarhalis, tetanus, difterija, hripavac, S. epidermidis, enterokoki, te S. aureus.
39. Cjepivo, naznačeno time što sadrži imunogeni pripravak u skladu s bilo kojim od patentnih zahtjeva 35-38.
40. Imunogeni pripravak u skladu s bilo kojim od patentnih zahtjeva 35-38 ili cjepivo u skladu s patentnim zahtjevom 39, naznačeni time što su namijenjeni upotrebi u liječenju ili sprječavanju bolesti koju uzrokuje bakterija C. difficile.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161490707P | 2011-05-27 | 2011-05-27 | |
| US201161490716P | 2011-05-27 | 2011-05-27 | |
| US201161490734P | 2011-05-27 | 2011-05-27 | |
| EP12726374.7A EP2714911B1 (en) | 2011-05-27 | 2012-05-25 | Immunogenic composition |
| PCT/EP2012/059805 WO2012163817A2 (en) | 2011-05-27 | 2012-05-25 | Immunogenic composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20170094T1 true HRP20170094T1 (hr) | 2017-03-24 |
Family
ID=46168484
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231749TT HRP20231749T1 (hr) | 2011-05-27 | 2012-05-25 | Imunogeni pripravak |
| HRP20170094TT HRP20170094T1 (hr) | 2011-05-27 | 2017-01-20 | Imunogeni pripravak |
| HRP20180339TT HRP20180339T1 (hr) | 2011-05-27 | 2018-02-23 | Imunogeni pripravak |
| HRP20191291TT HRP20191291T1 (hr) | 2011-05-27 | 2019-07-17 | Imunogeni pripravak |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231749TT HRP20231749T1 (hr) | 2011-05-27 | 2012-05-25 | Imunogeni pripravak |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180339TT HRP20180339T1 (hr) | 2011-05-27 | 2018-02-23 | Imunogeni pripravak |
| HRP20191291TT HRP20191291T1 (hr) | 2011-05-27 | 2019-07-17 | Imunogeni pripravak |
Country Status (25)
| Country | Link |
|---|---|
| US (5) | US9290565B2 (hr) |
| EP (6) | EP3138916B1 (hr) |
| JP (3) | JP5952390B2 (hr) |
| KR (1) | KR102014502B1 (hr) |
| CN (3) | CN103732750A (hr) |
| BR (2) | BR112013030396A2 (hr) |
| CA (2) | CA2837393A1 (hr) |
| CY (3) | CY1118599T1 (hr) |
| DK (4) | DK3564378T3 (hr) |
| EA (1) | EA030898B1 (hr) |
| ES (4) | ES2968455T3 (hr) |
| FI (1) | FI3564378T3 (hr) |
| HR (4) | HRP20231749T1 (hr) |
| HU (4) | HUE037126T2 (hr) |
| IL (1) | IL229529B2 (hr) |
| LT (4) | LT2714910T (hr) |
| ME (1) | ME02600B (hr) |
| MX (1) | MX346200B (hr) |
| PL (4) | PL2714911T3 (hr) |
| PT (4) | PT3564378T (hr) |
| RS (1) | RS55605B1 (hr) |
| SG (1) | SG195037A1 (hr) |
| SI (4) | SI2714911T1 (hr) |
| SM (1) | SMT201700110B (hr) |
| WO (3) | WO2012163817A2 (hr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112014004896B1 (pt) | 2010-09-03 | 2023-02-14 | Valneva Usa, Inc. | Polipepttdeo isolado de proteínas de toxina a e toxina b de c. difficile e usos do mesmo |
| PE20141029A1 (es) | 2011-04-22 | 2014-09-04 | Wyeth Llc | Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos |
| ES2704069T3 (es) | 2011-12-08 | 2019-03-14 | Glaxosmithkline Biologicals Sa | Vacuna basada en toxinas de Clostridium difficile |
| BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
| JP6290918B2 (ja) | 2012-12-05 | 2018-03-07 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物 |
| EP2988778A4 (en) * | 2013-04-22 | 2016-12-14 | Board Of Regents Of The Univ Of Oklahoma | CLOSTRIDIUM DIFFICILE IMPREGENT AND METHOD OF USE |
| US10533036B2 (en) | 2015-02-19 | 2020-01-14 | Immune Biosolutions Inc | Clostridium difficile toxins a and/or B antigen and epitope antibody, and pharmaceutical uses thereof |
| WO2019243307A1 (en) | 2018-06-19 | 2019-12-26 | Glaxosmithkline Biologicals Sa | Immunogenic composition |
| WO2023020993A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023020992A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| WO2023020994A1 (en) | 2021-08-16 | 2023-02-23 | Glaxosmithkline Biologicals Sa | Novel methods |
| GB202205833D0 (en) | 2022-04-21 | 2022-06-08 | Glaxosmithkline Biologicals Sa | Bacteriophage |
| WO2023232901A1 (en) | 2022-06-01 | 2023-12-07 | Valneva Austria Gmbh | Clostridium difficile vaccine |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| HUT78048A (hu) * | 1994-10-24 | 1999-07-28 | Ophidian Pharmaceuticals, Inc. | A C. difficile által okozott betegség kezelésére és megelőzésére szolgáló vakcina és antitoxin |
| CN1195297A (zh) * | 1995-07-07 | 1998-10-07 | 奥拉瓦克斯有限公司 | 艰难梭菌毒素作为粘膜佐剂 |
| WO2000061761A2 (en) * | 1999-04-09 | 2000-10-19 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
| JP2002542169A (ja) * | 1999-04-09 | 2002-12-10 | テクラブ， インコーポレイテッド | Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅに対する、組換え毒素Ａ／毒素Ｂワクチン |
| US20020065396A1 (en) | 2000-03-28 | 2002-05-30 | Fei Yang | Compositions and methods of diagnosing, monitoring, staging, imaging and treating colon cancer |
| US20120020996A1 (en) * | 2008-08-06 | 2012-01-26 | Jonathan Lewis Telfer | Vaccines against clostridium difficile and methods of use |
| WO2011060431A2 (en) | 2009-11-16 | 2011-05-19 | University Of Maryland Baltimore | Multivalent live vector vaccine against clostridium difficile-associated disease |
| BR112014004896B1 (pt) * | 2010-09-03 | 2023-02-14 | Valneva Usa, Inc. | Polipepttdeo isolado de proteínas de toxina a e toxina b de c. difficile e usos do mesmo |
| GB201016742D0 (en) * | 2010-10-05 | 2010-11-17 | Health Prot Agency | Clostridium difficile antigens |
-
2012
- 2012-05-25 HR HRP20231749TT patent/HRP20231749T1/hr unknown
- 2012-05-25 DK DK19179871.9T patent/DK3564378T3/da active
- 2012-05-25 HU HUE12724950A patent/HUE037126T2/hu unknown
- 2012-05-25 JP JP2014511899A patent/JP5952390B2/ja active Active
- 2012-05-25 EP EP16193340.3A patent/EP3138916B1/en not_active Revoked
- 2012-05-25 WO PCT/EP2012/059805 patent/WO2012163817A2/en active Application Filing
- 2012-05-25 US US14/122,690 patent/US9290565B2/en not_active Expired - Fee Related
- 2012-05-25 ME MEP-2017-26A patent/ME02600B/me unknown
- 2012-05-25 LT LTEP12724950.6T patent/LT2714910T/lt unknown
- 2012-05-25 MX MX2013013924A patent/MX346200B/es active IP Right Grant
- 2012-05-25 CA CA2837393A patent/CA2837393A1/en not_active Abandoned
- 2012-05-25 WO PCT/EP2012/059793 patent/WO2012163811A1/en active Application Filing
- 2012-05-25 PL PL12726374T patent/PL2714911T3/pl unknown
- 2012-05-25 SI SI201230868A patent/SI2714911T1/sl unknown
- 2012-05-25 PT PT191798719T patent/PT3564378T/pt unknown
- 2012-05-25 PT PT127263747T patent/PT2714911T/pt unknown
- 2012-05-25 ES ES19179871T patent/ES2968455T3/es active Active
- 2012-05-25 HU HUE16193340 patent/HUE044772T2/hu unknown
- 2012-05-25 SI SI201232050T patent/SI3564378T1/sl unknown
- 2012-05-25 CA CA2837395A patent/CA2837395C/en active Active
- 2012-05-25 ES ES16193340T patent/ES2743442T3/es active Active
- 2012-05-25 KR KR1020137034795A patent/KR102014502B1/ko active IP Right Grant
- 2012-05-25 JP JP2014511895A patent/JP2014516532A/ja active Pending
- 2012-05-25 WO PCT/EP2012/059792 patent/WO2012163810A1/en active Application Filing
- 2012-05-25 LT LTEP12726374.7T patent/LT2714911T/lt unknown
- 2012-05-25 SI SI201231247T patent/SI2714910T1/en unknown
- 2012-05-25 PT PT16193340T patent/PT3138916T/pt unknown
- 2012-05-25 ES ES12726374.7T patent/ES2615737T3/es active Active
- 2012-05-25 EA EA201391548A patent/EA030898B1/ru not_active IP Right Cessation
- 2012-05-25 EP EP23205566.5A patent/EP4296361A3/en active Pending
- 2012-05-25 SI SI201231642T patent/SI3138916T1/sl unknown
- 2012-05-25 CN CN201280037466.8A patent/CN103732750A/zh active Pending
- 2012-05-25 RS RS20170051A patent/RS55605B1/sr unknown
- 2012-05-25 DK DK12726374.7T patent/DK2714911T3/en active
- 2012-05-25 PL PL19179871.9T patent/PL3564378T3/pl unknown
- 2012-05-25 CN CN201280037472.3A patent/CN103717742B/zh active Active
- 2012-05-25 EP EP18150735.1A patent/EP3327126A1/en not_active Withdrawn
- 2012-05-25 BR BR112013030396A patent/BR112013030396A2/pt not_active IP Right Cessation
- 2012-05-25 EP EP12726374.7A patent/EP2714911B1/en not_active Revoked
- 2012-05-25 PT PT127249506T patent/PT2714910T/pt unknown
- 2012-05-25 CN CN201710239709.0A patent/CN107098977A/zh active Pending
- 2012-05-25 PL PL16193340T patent/PL3138916T3/pl unknown
- 2012-05-25 SG SG2013085386A patent/SG195037A1/en unknown
- 2012-05-25 HU HUE12726374A patent/HUE030823T2/en unknown
- 2012-05-25 US US14/122,345 patent/US9409974B2/en active Active
- 2012-05-25 DK DK12724950.6T patent/DK2714910T3/en active
- 2012-05-25 EP EP12724950.6A patent/EP2714910B1/en active Active
- 2012-05-25 LT LTEP16193340.3T patent/LT3138916T/lt unknown
- 2012-05-25 BR BR112013030395-6A patent/BR112013030395B1/pt active IP Right Grant
- 2012-05-25 PL PL12724950T patent/PL2714910T3/pl unknown
- 2012-05-25 FI FIEP19179871.9T patent/FI3564378T3/fi active
- 2012-05-25 LT LTEP19179871.9T patent/LT3564378T/lt unknown
- 2012-05-25 DK DK16193340.3T patent/DK3138916T3/da active
- 2012-05-25 ES ES12724950.6T patent/ES2660468T3/es active Active
- 2012-05-25 HU HUE19179871A patent/HUE064492T2/hu unknown
- 2012-05-25 EP EP19179871.9A patent/EP3564378B1/en active Active
-
2013
- 2013-11-21 IL IL229529A patent/IL229529B2/en unknown
-
2016
- 2016-02-11 US US15/041,924 patent/US9644024B2/en active Active
- 2016-06-09 JP JP2016114910A patent/JP2017012160A/ja active Pending
- 2016-06-28 US US15/194,937 patent/US10093722B2/en active Active
-
2017
- 2017-01-20 HR HRP20170094TT patent/HRP20170094T1/hr unknown
- 2017-02-03 CY CY20171100158T patent/CY1118599T1/el unknown
- 2017-02-16 SM SM201700110T patent/SMT201700110B/it unknown
- 2017-03-21 US US15/464,454 patent/US10377816B2/en active Active
-
2018
- 2018-02-15 CY CY20181100188T patent/CY1119916T1/el unknown
- 2018-02-23 HR HRP20180339TT patent/HRP20180339T1/hr unknown
-
2019
- 2019-07-17 HR HRP20191291TT patent/HRP20191291T1/hr unknown
- 2019-08-27 CY CY20191100909T patent/CY1121936T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170094T1 (hr) | Imunogeni pripravak | |
| HRP20200727T1 (hr) | Pripravci i metode povezane s varijantama proteina a (spa) | |
| US10588955B2 (en) | Streptococcus pneumoniae protein antigen, and preparation method and use thereof | |
| RU2016146801A (ru) | Вакцинная композиция против инфекции, вызванной streptococcus suis | |
| JP2013529077A5 (hr) | ||
| HRP20190907T1 (hr) | Imunogeni pripravak koji sadrži polipeptide iz panton-valentin leukocidina (pvl) | |
| JP2013529078A5 (hr) | ||
| JP2011500035A5 (hr) | ||
| RU2012153972A (ru) | Химерные гены ospa, белки и способы их применения | |
| JP2016504993A5 (hr) | ||
| JP2016522259A5 (hr) | ||
| RU2015106916A (ru) | Полипептиды clostridium difficile в виде вакцины | |
| JP2015529677A5 (hr) | ||
| Sharma et al. | Identification and immunogenic potential of B cell epitopes of outer membrane protein OmpF of Aeromonas hydrophila in translational fusion with a carrier protein | |
| JP2020509770A5 (hr) | ||
| JP2016515516A5 (hr) | ||
| Liu et al. | Immunological characterisation and immunoprotective efficacy of functional domain antigens of botulinum neurotoxin serotype A | |
| WO2012174455A3 (en) | Group a streptococcus multivalent vaccine | |
| AU2011304942B2 (en) | Fusion protein SAmB, coding gene and application thereof | |
| KR101635673B1 (ko) | Ａ형 간염 바이러스 백신 소재 단백질 ｖｐ1-3ｎ 및 백신 조성물 | |
| WO2013171661A3 (en) | Adjuvant formulations and methods | |
| Chen et al. | Designing, expression and immunological characterization of a chimeric protein of Mycoplasma pneumoniae | |
| JP2021505525A5 (hr) | ||
| Jang et al. | Expression and immunogenic analysis of recombinant polypeptides derived from capsid protein VP1 for developing subunit vaccine material against hepatitis A virus | |
| CN105254719A (zh) | 金黄色葡萄球菌trap蛋白的cd4+t细胞表位鉴定及其重组表位疫苗 |